Synergistic antitumor effect of liposomal-based formulations of olaparib and topotecan in primary epithelial ovarian cancer cells
Cancer Cell International,
Abstract Background Olaparib is a PARP inhibitor inducing synthetic lethality in tumors with deficient homologous recombination …